Correlation and survival analysis of SIRT1 expression level and clinicopathological features of breast cancer patients

doi:10.3877/cma.j.issn.1674-0793.2016.01.004

Abstract

Abstract:

Objective

To detect the expression of silent information regulator 1 (SIRT1) in breast cancer and adjacent paracancerous tissues, and to analyze the correlation between its expression level and other clinical features of breast cancer and its significance in prognosis.

Methods

The expression of SIRT1 was detected by immunohistochemistry in 120 breast cancer tissues and 53 adjacent paracancerous tissues. The difference between the two groups and the relationship between SIRT1 expression and other clinical features were tested by chi-square test. Survival analysis was calculated by Kaplan-Meier method, and the survival rate was compared by Log-rank test.

Results

The expression of SIRT1 in breast cancer group was significantly higher than adjacent paracancerous tissues group (53.3% vs 34.0%, χ²=5.533, P=0.02). SIRT1 expression level showed positive correlation with tumor size and expresion of Ki-67 (χ²=6.790, 21.316, P=0.009, 0.000), but no statistical correlation with lymph node metastasis, clinical stage, histological grade, ER, PR and Her-2 expression. Statistical analysis showed that compared with low SIRT1 expression, patients with high SIRT1 expression level had significantly poorer prognosis (χ²=9.320, P<0.05).

Conclusions

The expression of SIRT1 is obviously increased in breast cancer patients than that in adjacent paracancerous tissues, and its expression is correlated with tumor size and expression of Ki-67. These results may implicate that SIRT1 will improve the development of breast cancer and the high-er expression of SIRT1 indicates the activated proliferation and poor survival rate.

Key words: Breast neoplasms, Silent information regulaltor 1, Immuneohistochemistry

Ruilei Liu, Jianning Chen, Jiani Wang, Mi Tang, Yanling Zhang. Correlation and survival analysis of SIRT1 expression level and clinicopathological features of breast cancer patients[J]. Chinese Archives of General Surgery(Electronic Edition), 2016, 10(01): 31-35.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2016.01.004

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2016/V10/I01/31

Figures/Tables 3

References 18

2	Liu T,Liu PY,Marshall GM. The critical role of the class Ⅲ his-tone deacetylase SIRT1 in cancer[J]. Cancer Res, 2009, 69(5): 1702-1705.
3	Song NY,Surh YJ. Janus-faced role of SIRT1 in tumorigenesis[J]. Ann N Y Acad Sci, 2012, 1271: 10-19.
4	Deng CX. SIRT1, is it a tumor promoter or tumor suppressor?[J]. Int J Biol Sci, 2009, 5(2): 147-152.
5	张嘉庆,王殊,谢菲.不断提高我国乳腺癌综合治疗水平[J/CD].中华普外科手术学杂志:电子版, 2011, 5(4): 367-372.
6	Guarente L. Sir2 links chromatin silencing, metabolism, and aging[J]. Genes Dev, 2000, 14(9): 1021-1026.
7	Vaziri H,Dessain SK,Ng EE, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase[J]. Cell, 2001, 107(2): 149-159.
8	Kim EJ,Kho JH,Kang MR, et al. Active regulator of SIRT1 coop-erates with SIRT1 and facilitates suppression of p53 activity[J]. Mol Cell, 2007, 28(2): 277-290.
9	Sung JY,Kim R,Kim JE, et al. Balance between SIRT1 and DBC1 expression is lost in breast cancer[J]. Cancer Sci, 2010, 101(7): 1738-1744.
10	Zschoernig B,Mahlknecht U. SIRTUIN 1: regulating the regulator[J]. Biochem Biophys Res Commun, 2008, 376(2): 251-255.
11	Motta MC,Divecha N,Lemieux M, et al. Mammalian SIRT1 re-presses forkhead transcription factors[J]. Cell, 2004, 116(4): 551-563.
12	Dai JM,Wang ZY,Sun DC, et al. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity[J]. J Cell Physi-ol, 2007, 210(1): 161-166.
13	Wong S,Weber JD. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1[J]. Biochem J, 2007, 407(3): 451-460.
14	Li K,Casta A,Wang R, et al. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediat-ed deacetylation[J]. J Biol Chem, 2008, 283(12): 7590-7598.
15	Doyle SL,Donohoe CL,Lysaght J, et al.Visceral obesity, metabol-ic syndrome, insulin resistance and cancer[J]. Proc Nutr Soc, 2012, 71(1): 181-189.
16	Eades G,Yao Y,Yang M, et al. miR-200a regulates SIRT1 ex-pression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells[J]. J Biol Chem, 2011, 286(29): 25992-26002.
1	Jemal A,Bray F,Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
17	Nalls D,Tang SN,Rodova M, et al. Targeting epigenetic regula-tion of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells[J]. PLoS One, 2011, 6(8): e24099.
18	Huffman DM,Grizzle WE,Bamman MM, et al. SIRT1 is signifi-cantly elevated in mouse and human prostate cancer[J]. Cancer Res, 2007, 67(14): 6612-6618.

项目		例数	SIRT1蛋白		χ²值	P值
项目		例数	高表达	低表达	χ²值	P值
年龄（岁）		?	?	?	?	?
?	≤ 45	84	45(53.6)	39(46.4)	?	?
?	>45	36	19(52.8)	17(47.2)	6.006	0.936
肿瘤大小(cm)		?	?	?	?	?
?	≤2	26	8(30.8)	18(69.2)	?	?
?	>2	94	56(59.6)	38(40.4)	6.790	0.009^a
淋巴结转移		?	?	?	?	?
?	-	45	21(46.7)	24(53.3)	?	?
?	+	75	43(57.3)	32(42.7)	1.286	0.257
TNM分期		?	?	?	?	?
?	Ⅰ-Ⅱ	84	41(48.8)	43(51.2)	?	?
?	Ⅲ-Ⅳ	36	23(63.9)	13(36.1)	2.302	0.129
组织学分级		?	?	?	?	?
?	Ⅰ	12	6(50.0)	6(50.0)	?	?
?	Ⅱ	89	48(53.9)	41(46.1)	?	?
?	Ⅲ	19	10(52.6)	9(47.4)	6.070	0.966
ER		?	?	?	?	?
?	阴性	43	23(53.5)	20(46.5)	?	?
?	阳性	77	41(53.2)	36(46.8)	0.001	0.980
PR		?	?	?	?	?
?	阴性	49	30(61.2)	19(38.8)	?	?
?	阳性	71	34(47.9)	37(52.1)	2.072	0.150
Her-2		?	?	?	?	?
?	阴性	87	51(58.6)	36(41.4)	?	?
?	阳性	33	13(39.4)	20(60.6)	3.554	0.059
Ki-67		?	?	?	?	?
?	低表达	63	21(33.3)	42(66.7)	?	?
?	高表达	57	43(75.4)	14(24.6)	21.316	0.000^a

项目		例数	SIRT1蛋白		χ²值	P值
项目		例数	高表达	低表达	χ²值	P值
年龄（岁）		?	?	?	?	?
?	≤ 45	84	45(53.6)	39(46.4)	?	?
?	>45	36	19(52.8)	17(47.2)	6.006	0.936
肿瘤大小(cm)		?	?	?	?	?
?	≤2	26	8(30.8)	18(69.2)	?	?
?	>2	94	56(59.6)	38(40.4)	6.790	0.009^a
淋巴结转移		?	?	?	?	?
?	-	45	21(46.7)	24(53.3)	?	?
?	+	75	43(57.3)	32(42.7)	1.286	0.257
TNM分期		?	?	?	?	?
?	Ⅰ-Ⅱ	84	41(48.8)	43(51.2)	?	?
?	Ⅲ-Ⅳ	36	23(63.9)	13(36.1)	2.302	0.129
组织学分级		?	?	?	?	?
?	Ⅰ	12	6(50.0)	6(50.0)	?	?
?	Ⅱ	89	48(53.9)	41(46.1)	?	?
?	Ⅲ	19	10(52.6)	9(47.4)	6.070	0.966
ER		?	?	?	?	?
?	阴性	43	23(53.5)	20(46.5)	?	?
?	阳性	77	41(53.2)	36(46.8)	0.001	0.980
PR		?	?	?	?	?
?	阴性	49	30(61.2)	19(38.8)	?	?
?	阳性	71	34(47.9)	37(52.1)	2.072	0.150
Her-2		?	?	?	?	?
?	阴性	87	51(58.6)	36(41.4)	?	?
?	阳性	33	13(39.4)	20(60.6)	3.554	0.059
Ki-67		?	?	?	?	?
?	低表达	63	21(33.3)	42(66.7)	?	?
?	高表达	57	43(75.4)	14(24.6)	21.316	0.000^a

[1]	Yaping Jia, Shu'e Zeng. Ultrasound and pathological characteristics of breast metaplastic carcinoma containing squamous cell carcinoma components [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 844-848.
[2]	Wei Tang, Rongquan He, Suning Huang. Application of deep learning in imaging for diagnosis, treatment and prognosis prediction of breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 323-328.
[3]	Xia Kang, Hao Tian, Jin Qian, Yuan Gao, Hongming Miao, Xiaowei Qi. Osteorin attenuates osteolysis during bone metastasis of cancers through inhibiting osteoclastogenesis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 329-339.
[4]	Xiaoli Yi, Shasha Hu, Yan Zhang. Impact of HER-2 low expression on response of neoadjuvant chemotherapy and prognosis in breast cancer patients [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 340-346.
[5]	Jie Shi, Yuntao Li, Haiyan Gao. Prognosis of node-positive luminal A breast cancer patients with neoadjuvant and adjuvant chemotherapy and influencing factors [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(06): 353-361.
[6]	Jiaxuan Liu, Binghe Xu. Annual advancement of clinical research on breast cancer in China [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 259-265.
[7]	Chengcai Yao, Changchun Liu, Wenjian Huang, Ming Chen. Single-port non-lipolysis fluorescence-guided laparoscopy for axillary lymph node biopsy in early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 266-271.
[8]	Bohui Shi, Xiping Ding, Lian Wang, Rong Li, Pingli Guo, Jing Qi, Yao Chen, Na Hao, Yu Ren. Summary of best evidences for prevention and treatment of subcutaneous seroma after breast cancer surgery [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(05): 277-284.
[9]	Yaping Wang, Jing Fan, Niuniu Hou, Rui Ling. Clinical significance of tumor-infiltrating lymphocytes in HER-2-positive early breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(04): 203-209.
[10]	Wenbo Gao, Ming Li, Yunhao Zhang. Prognostic value and clinical significance of advanced lung cancer inflammation index in patients with triple negative breast cancer [J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(04): 210-217.
[11]	Qinqin Zhang, Junnan Wang, Houmin Lin, Ying Wu, Yuemei Tan, Mingzhou Li, Junfei Jin, Ningxia Wang, Yong Hong. Bioinformatics analysis of differential expression and clinical significance of complement 3 in breast cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 271-277.
[12]	Qingyan Yan, Xiaomei Yong, Hong Luo, Min Du. Prognostic factors and survival analysis of multicenter elderly patients with metastatic breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 636-638.
[13]	Zhiming Li, Chenming Guo, Xiaochen Zhuang, Xueqin Hou, Junxi Gao. Comparative study of qualitative and quantitative indicators of contrast-enhanced ultrasound in early breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 639-643.
[14]	Hongbo Qu, Fang Zhu, Zhe Xu, Nan Wu, Jianhuai He, Xianming Wang. Application of subclavian lymph node dissection through intermuscular approach in locally advanced breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 510-513.
[15]	Shan Chen, Zhiqiang Hu, Yueming Zhang, Ding Tang, Meng Li, Shuai Zhao. Expression of Orai1 and Orai3 in breast cancer and their correlation with pathological indexes [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 514-517.

Please choose a citation manager

Content to export